Form 4: Akebia Therapeutics CMO Sells Shares for Tax Obligations

Akebia Therapeutics' Chief Medical Officer, Steven Burke, sold 67,658 shares of common stock for tax withholding purposes related to RSU vesting.

Summary

• Steven Keith Burke, SVP, Chief Medical Officer of Akebia Therapeutics, Inc. (AKBA), sold a total of 67,658 shares of common stock.
• The sales occurred on February 2, 2026, at a price of $1.39 per share.
• These transactions were executed automatically by the Issuer to cover tax withholding obligations.
• The sales were connected to the vesting and settlement of one-third of Mr. Burke's restricted stock units (RSUs) granted on January 31, 2023, January 31, 2024, and January 31, 2025.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on November 17, 2023.
• Following these transactions, Mr. Burke beneficially owns 948,432 shares of Akebia Therapeutics common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it's a sale of shares by an insider, it's for tax purposes related to RSU vesting and executed under a 10b5-1 plan, which is a routine and expected occurrence.

Positives

• The sales were for tax withholding purposes, indicating the vesting of restricted stock units, which is a positive for the executive.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, demonstrating planned and compliant insider trading.

Negatives

• The sale of 67,658 shares by a senior executive, even for tax purposes, reduces their direct ownership in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider sales for tax withholding purposes, especially when conducted under a Rule 10b5-1 plan, are common across all industries and generally do not reflect a change in management's confidence in the company's long-term prospects. This transaction is typical for executives receiving equity compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact as the sale is routine for tax purposes and not indicative of a change in company fundamentals or executive sentiment.
• Employees: No direct impact beyond the reporting person.

Key Dates

Recommendation

The filing details a routine insider stock sale for tax withholding purposes, executed under a pre-arranged 10b5-1 plan. This type of transaction is not indicative of a change in the company's fundamental outlook or the executive's confidence, and therefore does not warrant a change in investment recommendation based solely on this filing. Investors should continue to hold and monitor broader company performance and market conditions.

Keywords

Akebia Therapeutics, AKBA, Steven Keith Burke, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding, Rule 10b5-1 Plan, Officer Transaction